Free Trial
NASDAQ:BIOL

BIOLASE 3/21/2024 Earnings Report

BIOLASE logo
$0.0099 0.00 (-1.00%)
As of 07/11/2025

BIOLASE EPS Results

Actual EPS
-$1.76
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BIOLASE Revenue Results

Actual Revenue
$13.49 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BIOLASE Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BIOLASE's next earnings date is estimated for Wednesday, August 6, 2025, based on past reporting schedules.

Conference Call Resources

BIOLASE Earnings Headlines

Biolase Inc (BIOLQ)
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Biolase Inc. Faces Bankruptcy Amid Strategic Asset Sale
Sonendo, Inc. Reports Third Quarter 2024 Financial Results
See More BIOLASE Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BIOLASE? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BIOLASE and other key companies, straight to your email.

About BIOLASE

BIOLASE (NASDAQ:BIOL) (NASDAQ: BIOL) is a medical device company specializing in the development, manufacture and sale of laser-based systems for dental and medical applications. The company’s flagship offerings include all-tissue laser platforms such as the Waterlase® family, which combine laser energy with a stream of water to perform cutting, debridement and other clinical procedures with reduced pain and enhanced healing. In addition to all-tissue systems, BIOLASE markets diode-based laser devices for soft‐tissue surgery, periodontal therapy, endodontics and teeth whitening, along with a range of accessories and consumables designed to optimize clinical performance and patient outcomes.

BIOLASE’s product portfolio extends beyond hardware to encompass software-driven treatment protocols, training programs and digital imaging integration, supporting dental professionals in expanding their clinical capabilities. The company operates a comprehensive service network that provides installation, maintenance and technical support, as well as on‐site and online education for practitioners. Through a combination of direct sales and distribution partnerships, BIOLASE reaches private practices, group practices, academic institutions and government facilities worldwide.

Founded in the early 1980s, BIOLASE initially focused on the research and commercialization of medical lasers before pivoting its efforts toward dental applications in the early 2000s. The company went public in the 1990s and has since broadened its presence through strategic acquisitions and international expansion. BIOLASE’s headquarters are located in Irvine, California, and its operations span North America, Europe, Asia-Pacific and Latin America, with regional offices and authorized distributors in key markets such as Germany, Japan, China and Brazil.

BIOLASE is overseen by a board of directors and led by an experienced executive team with deep expertise in medical technology, regulatory affairs and global commercialization. The senior leadership remains focused on advancing laser dentistry through ongoing research and development, expanding the installed base of clinical systems and enhancing customer support programs. By emphasizing innovation, clinical education and strategic partnerships, BIOLASE aims to drive long-term adoption of laser therapies in dental and medical specialties around the world.

View BIOLASE Profile

More Earnings Resources from MarketBeat